Almac Pharma Services, part of the global contract pharmaceutical development and manufacturing organisation, the Almac Group, is inviting members of the pharmaceutical and biotechnology industry to join its upcoming complimentary workshop series this September.
Craigavon, U.K., 01 Aug 2019 – Almac Pharma Services, part of the global contract pharmaceutical development and manufacturing organisation, the Almac Group, is inviting members of the pharmaceutical and biotechnology industry to join its upcoming complimentary workshop series this September.
During these specifically designed knowledge sharing sessions, Almac’s subject matter experts will guide participants through the product launch timeline from Phase 3 to commercial launch and share valuable insights into the key requirements and considerations to ensure commercial launch in Europe is successful.
The three individual sessions will be hosted on Monday 16th September in the Hilton San Fran Airport Bayfront, San Francisco, CA; the Marriot La Jolla hotel, San Diego, CA on Tuesday 17th September with the final workshop taking place on Thursday 19th September in the Pan Pacific hotel, Seattle, WA.
Almac understands that launching drug product can be challenging, especially if sponsors are not familiar with the key milestone requirements that should be met at various time points in the MA submission process. Using real-life scenarios and interactive group discussions, participants will learn about the European regulatory framework and how this determines all launch milestones, understand the importance of the Qualified Person (QP) and QP declarations and identify top operational considerations as you progress to commercialisation and much more.
Workshop host, Adam Schroeder, Director of Business Development at Almac Pharma Services, commented on the upcoming workshop: “We are excited to offer this series of workshops in three significant locations across the west coast. The combination of interactive presentations, round table discussions and networking at these events will prove invaluable for participants wishing to find out more about launching their product into Europe. We look forward to sharing our industry insights and expertise with those attending in September.”
To find out more and to sign up, please visit here.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.
